Nelmastobart with chemo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- Your colorectal cancer has spread or come back, and you've already tried key chemotherapy drugs (oxaliplatin and irinotecan) or aren't able to take them.
- You are able to do most daily activities (ECOG 0 or 1).
- Your blood counts, kidney, and liver function are within certain safe limits.
- You have not taken trifluridine/tipiracil for your cancer before, or it didn't stop working while you were on it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
This trial tests a new drug called nelmastobart combined with two standard chemotherapy drugs (TAS-102 and bevacizumab) for people with colorectal cancer that has spread or returned and hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.